Effects of nattokinase on blood pressure: a randomized, controlled trial
- PMID: 18971533
- DOI: 10.1291/hypres.31.1583
Effects of nattokinase on blood pressure: a randomized, controlled trial
Abstract
The objective of this study was to examine the effects of nattokinase supplementation on blood pressure in subjects with pre-hypertension or stage 1 hypertension. In a randomized, double-blind, placebo-controlled trial, 86 participants ranging from 20 to 80 years of age with an initial untreated systolic blood pressure (SBP) of 130 to 159 mmHg received nattokinase (2,000 FU/capsule) or a placebo capsule for 8 weeks. Seventy-three subjects completed the protocol. Compared with the control group, the net changes in SBP and diastolic blood pressure (DBP) were -5.55 mmHg (95% confidence interval [CI], -10.5 to -0.57 mmHg; p<0.05) and -2.84 mmHg (CI, -5.33 to -0.33 mmHg; p<0.05), respectively, after the 8-week intervention. The corresponding net change in renin activity was -1.17 ng/mL/h for the nattokinase group compared with the control group (p<0.05). In conclusion, nattokinase supplementation resulted in a reduction in SBP and DBP. These findings suggest that increased intake of nattokinase may play an important role in preventing and treating hypertension.
Similar articles
-
Effects of black soy peptide supplementation on blood pressure and oxidative stress: a randomized controlled trial.Hypertens Res. 2013 Dec;36(12):1060-6. doi: 10.1038/hr.2013.79. Epub 2013 Aug 8. Hypertens Res. 2013. PMID: 23924691 Clinical Trial.
-
Antihypertensive effects of continuous oral administration of nattokinase and its fragments in spontaneously hypertensive rats.Biol Pharm Bull. 2011;34(11):1696-701. doi: 10.1248/bpb.34.1696. Biol Pharm Bull. 2011. PMID: 22040882
-
Consumption of nattokinase is associated with reduced blood pressure and von Willebrand factor, a cardiovascular risk marker: results from a randomized, double-blind, placebo-controlled, multicenter North American clinical trial.Integr Blood Press Control. 2016 Oct 13;9:95-104. doi: 10.2147/IBPC.S99553. eCollection 2016. Integr Blood Press Control. 2016. PMID: 27785095 Free PMC article.
-
Placebo effect and efficacy of nebivolol in patients with hypertension not controlled with lisinopril or losartan: a phase IV, randomized, placebo-controlled trial.Am J Cardiovasc Drugs. 2013 Apr;13(2):129-40. doi: 10.1007/s40256-013-0010-y. Am J Cardiovasc Drugs. 2013. PMID: 23519546 Clinical Trial.
-
[Progress in separation and purification of nattokinase and its enzyme activity determination].Se Pu. 2019 Mar 8;37(3):274-278. doi: 10.3724/SP.J.1123.2018.11010. Se Pu. 2019. PMID: 30900855 Review. Chinese.
Cited by
-
A single-dose of oral nattokinase potentiates thrombolysis and anti-coagulation profiles.Sci Rep. 2015 Jun 25;5:11601. doi: 10.1038/srep11601. Sci Rep. 2015. PMID: 26109079 Free PMC article. Clinical Trial.
-
Fibrin and Fibrinolytic Enzyme Cascade in Thrombosis: Unravelling the Role.Life (Basel). 2023 Nov 11;13(11):2196. doi: 10.3390/life13112196. Life (Basel). 2023. PMID: 38004336 Free PMC article. Review.
-
Pharmacologic vitreolysis.J Ophthalmic Vis Res. 2010 Jan;5(1):44-52. J Ophthalmic Vis Res. 2010. PMID: 22737326 Free PMC article.
-
Effective management of atherosclerosis progress and hyperlipidemia with nattokinase: A clinical study with 1,062 participants.Front Cardiovasc Med. 2022 Aug 22;9:964977. doi: 10.3389/fcvm.2022.964977. eCollection 2022. Front Cardiovasc Med. 2022. PMID: 36072877 Free PMC article.
-
Probiotic properties of Bacillus subtilis DG101 isolated from the traditional Japanese fermented food nattō.Front Microbiol. 2023 Sep 28;14:1253480. doi: 10.3389/fmicb.2023.1253480. eCollection 2023. Front Microbiol. 2023. PMID: 37840737 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Medical